Loading...
XNASAIMD
Market cap6mUSD
Dec 26, Last price  
0.48USD
1D
2.50%
1Q
-4.18%
Jan 2017
-64.52%
Name

Ainos Inc

Chart & Performance

D1W1MN
XNAS:AIMD chart
P/E
—
P/S
55.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.52%
Rev. gr., 5y
9.46%
Revenues
122k
-96.53%
51,506154,565133,94270,069109,83652,2545,15058,395530001,9750250,92877,72411,73116,563594,5633,519,627122,112
Net income
-14m
L-1.90%
-595,205-669,011-2,777,661-2,506,073-1,923,067-2,971,207506,312-1,313,773-650,847-622,602-622,602-521,874-669,982-617,375-1,338,639-1,582,183-1,460,811-3,904,803-14,037,168-13,770,549
CFO
-5m
L+55.39%
-328,052-655,391-1,461,207-1,412,052-948,811-903,114-584,538-309,705-489,442-664,248-554,981-366,414-520,808-542,703-1,009,198-909,476-499,551-1,249,977-3,021,183-4,694,668
Earnings
Mar 06, 2025

Profile

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
URL
https://www.ainos.com/
IPO date
Aug 08, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
122
-96.53%
3,520
491.97%
595
3,489.71%
Cost of revenue
13,329
8,960
2,105
Unusual Expense (Income)
NOPBT
(13,206)
(5,441)
(1,510)
NOPBT Margin
Operating Taxes
800
30
16
Tax Rate
NOPAT
(13,207)
(5,471)
(1,526)
Net income
(13,771)
-1.90%
(14,037)
259.48%
(3,905)
167.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
(301)
46,000
46,000
BB yield
0.00%
-544.05%
-725.15%
Debt
Debt current
42
1,261
3,590
Long-term debt
5,922
16
61
Deferred revenue
Other long-term liabilities
136
Net debt
4,078
(577)
1,899
Cash flow
Cash from operating activities
(4,695)
(3,021)
(1,250)
CAPEX
(93)
(634)
(144)
Cash from investing activities
(102)
(630)
(181)
Cash from financing activities
4,924
3,831
3,154
FCF
(12,708)
(30,446)
22,007
Balance
Cash
1,886
1,853
1,751
Long term investments
Excess cash
1,880
1,677
1,722
Stockholders' equity
(38,108)
(24,117)
(8,659)
Invested Capital
68,655
60,014
22,477
ROIC
ROCE
EV
Common stock shares outstanding
4,098
2,727
1,510
Price
2.05
-33.87%
3.10
-26.19%
4.20
393.93%
Market cap
8,401
-0.64%
8,455
33.29%
6,344
1,273.59%
EV
12,479
7,878
8,242
EBITDA
(8,335)
(607)
534
EV/EBITDA
15.43
Interest
144
54
19
Interest/NOPBT